Immix Biopharma Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

IMMX$8.57+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023

Condensed Consolidated Balance Sheets

	March 31, 2024	December 31, 2023
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$29,319,233	$17,509,791
Tax receivable	2,024,726	1,172,183
Prepaid expenses and other current assets	1,571,303	1,105,776
Total current assets	32,915,262	19,787,750
Other assets	20,418	-
Deferred offering cost	-	87,229
Right-of-use asset, net	1,051,078	-
Property and equipment, net	360,834	50,181
Total assets	$34,347,592	$19,925,160
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$5,622,501	$3,721,783
Operating lease liability - current	34,284	-
Total current liabilities	5,656,785	3,721,783
Operating lease liability – long term	1,058,944	-
Total liabilities	6,715,729	3,721,783
Commitments and contingencies	-	-
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, $0.0001 par value; 200,000,000 shares authorized; 26,468,783 shares issued and 26,396,420 shares outstanding at March 31, 2024 and 19,994,719 shares issued and 19,922,356 shares outstanding at December 31, 2023	2,648	2,000
Additional paid-in capital	86,593,132	69,779,706
Accumulated other comprehensive income	89,614	134,666
Accumulated deficit	(58,670,286)	(53,411,295)
Treasury stock at cost, 72,363 shares as of March 31, 2024 and December 31, 2023	(99,963)	(99,963)
Total Immix Biopharma, Inc. stockholders’ equity	27,915,145	16,405,114
Non-controlling interests	(283,282)	(201,737)
Total stockholders’ equity	27,631,863	16,203,377
Total liabilities and stockholders’ equity	$34,347,592	$19,925,160

Immix Biopharma, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

	For the Three Months Ended
	March 31,
	2024	2023
Operating expenses:
General and administrative expenses	$2,341,464	$1,201,734
Research and development	3,248,669	1,319,020
Total operating expenses	5,590,133	2,520,754
Loss from operations	(5,590,133)	(2,520,754)
Other income (expense):
Interest income	267,908	27,892
Total other income (expense), net	267,908	27,892
Loss before provision for income taxes	(5,322,225)	(2,492,862)
Provision for income taxes	8,839	5,170
Net loss	(5,331,064)	(2,498,032)
Net loss attributable to non-controlling interests	72,073	18,368
Net loss attributable to Immix Biopharma, Inc. common stockholders	(5,258,991)	(2,479,664)
Other comprehensive income (loss):
Foreign currency translation	(45,052)	(4,474)
Total other comprehensive loss	(45,052)	(4,474)
Comprehensive loss	(5,304,043)	(2,484,138)
Less: comprehensive loss attributable to non-controlling interests	-	-
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	$(5,304,043)	$(2,484,138)
Loss per common share - basic and diluted	$(0.22)	$(0.18)
Weighted average shares outstanding - basic and diluted	23,438,143	13,897,184

Immix Biopharma, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

For the Three Months Ended March 31, 2024 and 2023

Common · Additional · Accumulated Other · Treasury · Non- · Total
Common · Stock · Paid-in · Comprehensive · Accumulated · Treasury · Stock · Controlling · Stockholders’
Shares · Amount · Capital · Income · Deficit · Shares · Amount · Interests · Equity
Balance December 31, 2023	19,994,719	$2,000	$69,779,706	$134,666	$(53,411,295)	(72,363)	$(99,963)		$(201,737)	$16,203,377
Shares issued under ATM facility for cash proceeds, net of offering costs	68,302	7	338,488	-	-	-	-		-	338,495
Shares issued under public offering for cash proceeds, net of offering costs	6,319,025	632	15,519,722	-	-	-	-		-	15,520,354
Shares issued for exercise of stock options	1,251	-	2,489	-	-	-	-		-	2,489
Shares issued for services	85,486	9	327,367	-	-	-	-		-	327,376
Stock-based compensation	-	-	615,888	-	-	-	-		-	615,888
Non-controlling interests in subsidiary	-	-	9,472	-	-	-	-		(9,472)	-
Net loss	-	-	-	-	(5,258,991)	-	-		(72,073)	(5,331,064)
Foreign currency translation adjustment	-	-	-	(45,052)	-	-	-		-	(45,052)
Balance March 31, 2024	26,468,783	$2,648	$86,593,132	$89,614	$(58,670,286)	(72,363)	$(99,963)		$(283,282)	$27,631,863
Balance December 31, 2022	13,964,485	$1,397	$51,156,597	$87,021	$(37,985,247)	(72,363)	$(99,963)	$	-	$13,159,805
Shares issued under ATM facility for cash proceeds, net of offering costs	50,000	5	101,318	-	-	-	-		-	101,323
Nexcella shares issued for cash proceeds	-	-	650,000	-	-	-	-		-	650,000
Stock-based compensation	6,700	1	329,918	-	-	-	-		-	329,919
Non-controlling interests in subsidiary	-	-	13,990	-	-	-	-		(13,990)	-
Net loss	-	-	-	-	(2,479,664)	-	-		(18,368)	(2,498,032)
Foreign currency translation adjustment	-	-	-	(4,474)	-	-	-		-	(4,474)
Balance March 31, 2023	14,021,185	$1,403	$52,251,823	$82,547	$(40,464,911)	(72,363)	$(99,963)		$(32,358)	$11,738,541

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.